{"created":"2023-06-19T12:07:58.525340+00:00","id":14117,"links":{},"metadata":{"_buckets":{"deposit":"be9ae06b-a9c1-4ef7-a194-5d73ebd1f093"},"_deposit":{"created_by":17,"id":"14117","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"14117"},"status":"published"},"_oai":{"id":"oai:kokushikan.repo.nii.ac.jp:00014117","sets":["928:13:36:1144"]},"author_link":["21921","21922","21923","21924"],"item_10002_biblio_info_168":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-03-31","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"21","bibliographicPageStart":"15","bibliographicVolumeNumber":"37","bibliographic_titles":[{"bibliographic_title":"国士舘大学体育研究所報"},{"bibliographic_title":"The annual reports of health physical education and sport science","bibliographic_titleLang":"en"}]}]},"item_10002_description_151":{"attribute_name":"著者ID","attribute_value_mlt":[{"subitem_description":"J-GLOBAL ID : 200901011395643320","subitem_description_type":"Other"},{"subitem_description":"J-GLOBAL ID : 200901012516528555","subitem_description_type":"Other"},{"subitem_description":"　","subitem_description_type":"Other"},{"subitem_description":"J-GLOBAL ID : 201701008130248251","subitem_description_type":"Other"}]},"item_10002_description_161":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Cilostazol (CL) is an antithrombotic agent that was approved for prescribing under Japan’s national health insurance system in 2000. Clinical and experimental studies of CL to treat Alzheimer’s disease (AD) have been reported since 2009.\nAims: To use the propensity score method to ascertain whether CL reduced medical expenses among patients with AD in a prefecture of Japan.\nMethods: Records of 21,181 patients with AD (6,484 males and 14,697 females) from April 2010 to March 2011 were selected from a claims database of the National Health Insurance and the Long-term Care Insurance systems in a prefecture in Japan. Covariates were patient characteristics, comorbidities, and drugs prescribed for AD, i.e. psychoactive agents, narcotics, anticonvulsants, or cholinesterase inhibitors. The outcome variable was medical expenses for the whole year.\nResults: The propensity score indicated that patients receiving CL had medical expenses ¥10.9 higher than those of patients not receiving CL.\nConclusion: According to the propensity score method, CL did not efficiently reduce medical expenses for patients with AD based on claims data.","subitem_description_type":"Abstract"}]},"item_10002_description_180":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_10002_heading_148":{"attribute_name":"見出し","attribute_value_mlt":[{"subitem_heading_banner_headline":"原著","subitem_heading_language":"ja"},{"subitem_heading_banner_headline":"Original","subitem_heading_language":"en"}]},"item_10002_publisher_169":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"国士舘大学体育学部附属体育研究所"}]},"item_10002_source_id_170":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0389-2247","subitem_source_identifier_type":"PISSN"}]},"item_10002_source_id_172":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00089533","subitem_source_identifier_type":"NCID"}]},"item_10002_subject_177":{"attribute_name":"NDC","attribute_value_mlt":[{"subitem_subject":"499.09","subitem_subject_scheme":"NDC"},{"subitem_subject":"493.758","subitem_subject_scheme":"NDC"}]},"item_10002_textarea_160":{"attribute_name":"著作関係者詳細","attribute_value_mlt":[{"subitem_textarea_value":"Toshiaki KAMINAKA   Research and Education Center for Natural Sciences  Keio University"}]},"item_10002_textarea_184":{"attribute_name":"注記","attribute_value_mlt":[{"subitem_textarea_value":"表紙の表記 : 第37巻 (平成30年度)"}]},"item_10002_version_type_181":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KUBOYAMA, Izumi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"21921","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"ITO, Susumu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"21922","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"KAMINAKA, Toshiaki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"21923","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"HATA, Katsuhiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"21924","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-07-22"}],"displaytype":"detail","filename":"0389_2247_037_03.pdf","filesize":[{"value":"295.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","url":"https://kokushikan.repo.nii.ac.jp/record/14117/files/0389_2247_037_03.pdf"},"version_id":"2868dd7a-bed3-46a1-becb-b784a0ab9cbd"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Alzheimer's disease","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"cilostazol","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"medical cost","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"propensity score","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Medical expenses for cilostazol to treat Alzheimer's disease in Japan","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Medical expenses for cilostazol to treat Alzheimer's disease in Japan","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"17","path":["1144"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-07-22"},"publish_date":"2019-07-22","publish_status":"0","recid":"14117","relation_version_is_last":true,"title":["Medical expenses for cilostazol to treat Alzheimer's disease in Japan"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2024-03-15T02:21:29.586020+00:00"}